title: [Vascular endothelial growth factor antisense oligodeoxynucleotide enhance drug-sensitivity of myeloid leukemia cells to homoharringtonine].
abstract: OBJECTIVE
  To explore the effects of antisense phosphorothioate oligodeoxynucleotides (AS PS-ODN) of vascular endothelial growth factor (VEGF) on drug-sensitivity of AML and CML cells to homoharringtonine and its possible mechanism.
  
  
  METHODS
  A7, which was the most effective AS PS-ODN selected by computer aid-designing and experimental assay, contains 20-mer modified with phosphorothioate. It was transferred into cells by lipofectin while cultured in 2% serum medium for 8 h and then in 10% serum medium. Twenty four hours later, homoharringtonine was added into the culture and cultured for another 48 h. Cell viability was detected by trypan blue exclusion every 24 hours, cell apoptosis by flow cytometry, and level of VEGF protein by a VEGF ELISA kit.
  
  
  RESULTS
  The combination of A7 and homoharringtonine was able to inhibit cell survival (AML cell survival reduced 38%, CML cell survival reduced 25%), down-regulate VEGF protein expression (VEGF protein expression of AML cell and CML cell declined 25.44% and 30.81%, respectively) and increase homoharringtonine induced apoptosis in both AML and CML cells (apoptotic rates of AML and CML cells increased 48.29% and 52.76%, respectively).
  
  
  CONCLUSIONS
  The VEGF AS PS-ODN is able to enhance the drug-sensitivity to homoharringtonine, suggesting that inner VEGF proteins in myeloid leukemia cells had a drug-resistant effect.
authors.affiliation: Institute of Hematology, Medical College of Jinan University, Guangzhou 510632, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Fei
authors.forename: Huan
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000208:Acute Disease; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005260:Female; D006248:Harringtonines / Q000494:pharmacology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000473:pathology; D007951:Leukemia, Myeloid / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016376:Oligonucleotides, Antisense / Q000235:genetics*; D014162:Transfection / Q000379:methods; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D055815:Young Adult
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D006248:Harringtonines; D016376:Oligonucleotides, Antisense; D042461:Vascular Endothelial Growth Factor A